Zidovudine/Lamivudine (Combivir)

Overview | News | Research

Overview

Prescribing Information for Zidovudine/Lamivudine (Combivir) (PDF) (November 2011)
From ViiV Healthcare

News

FDA Approval of Generic ARVs: Nevirapine and Combivir Now Off-Patent in the U.S. (May/June 2012)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
Surprise! It's Generic Combivir! (May 26, 2011)
From Journal Watch
Approval of Generic Formulation of Lamivudine and Zidovudine Tablets, 150 mg/300 mg (May 25, 2011)
From U.S. Food and Drug Administration
Indian Pharmaceutical Company Receives Tentative Drug Approval Under PEPFAR (November 1, 2010)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
Ziagen Pills Packaged as Combivir (March 29, 2007)
From U.S. Food and Drug Administration

Research

Clinical Trials Using Combivir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health
Switch Studies (SWEET and BICOMBO) Explore Metabolic Issues (July 25, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Zidovudine/Lamivudine Inferior as First-Line NRTI Backbone (August 15, 2006)
In XVI International AIDS Conference
In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
In The XV International AIDS Conference, from TheBodyPRO.com
Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here.
From U.S. National Institute of Allergy and Infectious Diseases
Adherence to Combivir as Post-Exposure Prophylaxis in Non-Occupational HIV Exposures (July 8, 2002)
In The XIV International AIDS Conference, from TheBodyPRO.com

VIEW ALL ARTICLES

MOST VIEWED ARTICLES

	Scientists Crack HIV's Coating
	HIV Management Today: Cardiovascular Risk Management in HIV Care: Facing Reality
	Enough With the HIV Treatment Cascade Research, Let's Do Something About It Already: A Blog Entry by Lisa Fitzpatrick, M.D., M.P.H.
	HIV Eradication Moves One Small Step Closer as Stem Cell Transplant Findings Titillate
	New Danish Results Spark Interest for Future HIV Cure Research
	Liquid Injectable Silicone Effective, Safe for Treating HIV Patients With Facial Lipoatrophy: Study

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.